Citations

Clear

1792 citation(s) found for "Stephanie".

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Friedberg, Jonathan W. , Sharman, Jeff P. , Sweetenham, John , Johnston, Patrick B. , LaCasce, Ann S. , Schaefer-Cutillo, Julia, Vos, Sven de , Sinha, Rajni, Leonard, John P. , Cripe, Larry D., Gregory, Stephanie A., Sterba, Michael, Lowe, Ann M., Levy, Ronald , Vose, Julie M. , Shipp, Margaret Ann

Mayo Clinic

Blood | November 18, 2009 | Volume: 115 | Issue: 13 | Pages: 2578-2585

10.1182/blood-2009-08-236471 | PMID 19965662 Get It

AbstractCertain malignant B cells rely on B-cell receptor (BCR)–mediated survival signals. Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in vivo analyses of B-cell lymphoma cell lines and primary tumors, Syk inhibition induces apoptosis. These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL). Dose-limiting toxicity in the phase 1 portion was neutropenia, diarrhea, and thrombocytopenia, and 200 mg twice daily was chosen for phase 2 testing. Sixty-eight patients with recurrent B-NHL were then enrolled in 3 cohorts: (1) diffuse large B-cell lymphoma (DLBCL), (2) follicular lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphomas, and small lymphocytic leukemia/chronic lymphocytic leukemia (SLL/CLL). Common toxicities included diarrhea, fatigue, cytopenias, hypertension, and nausea. Objective response rates were 22% (5 of 23) for DLBCL, 10% (2 of 21) for FL, 55% (6 of 11) for SLL/CLL, and 11% (1/9) for MCL. Median progression-free survival was 4.2 months. Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL. This trial was registered at www.clinicaltrials.gov as #NCT00446095.
Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Rodents and Nonhuman Primates
Jenks, Nathan, Myers, Rae, Greiner, Suzanne , Thompson, Jill , Mader, Emily K., Greenslade, Andrew, Griesmann, Guy E., Federspiel, Mark J. , Rakela, Jorge , Vile, Richard G. , Barber, Glen N. , Meier, Thomas R., Blanco, Michael C., Carlson, Stephanie K., Russell, Stephen J. , Peng, Kah-Whye , Jenks, Nathan J., Borad, Mitesh J. , Russell, Stephen J

Mayo Clinic

Human Gene Therapy | November 13, 2009 | Volume: 21 | Issue: 4 | Pages: 451-462

10.1089/hum.2009.111 | PMID 19911974 Get It

Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines
Nehete, Pramod N. , Nehete, Bharti P. , Buchl, Stephanie J., Palmer, Donna , Montefiori, David C. , Ng, Philip , Sastry, K. Jagannadha , Barry, Michael A. , Weaver, Eric A. , Weaver, Eric A , Barry, Michael A

Mayo Clinic

Viruses | November 10, 2009 | Volume: 1 | Issue: 3 | Pages: 920-938

10.3390/v1030920 | PMID 20107521 Get It

Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5-immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Cooper, David S. , Doherty, Gerard M. , Haugen, Bryan R. , Kloos, Richard T. , Lee, Stephanie L. , Mandel, Susan J., Mazzaferri, Ernest L. , McIver, Bryan, Pacini, Furio , Schlumberger, Martin , Sherman, Steven I. , Steward, David L. , Tuttle, R. Michael , Kloos, Richard T , Sherman, Steven I

Mayo Clinic

Thyroid | October 27, 2009 | Volume: 19 | Issue: 11 | Pages: 1167-1214

10.1089/thy.2009.0110 | PMID 19860577 Get It

Nicotine response genetics in the zebrafish
Petzold, Andrew M. , Balciunas, Darius , Sivasubbu, Sridhar , Clark, Karl J. , Bedell, Victoria M. , Westcot, Stephanie, Myers, Shelly R., Moulder, Gary, Thomas, Mark J. , Ekker, Stephen C. , Ekker, Stephen C , Clark, Karl J , Balciunas, Darius

Mayo Clinic

Proceedings of the National Academy of Sciences | October 26, 2009 | Volume: 106 | Issue: 44 | Pages: 18662-18667

10.1073/pnas.0908247106 | PMID 19858493 Get It

Tobacco use is predicted to result in over 1 billion deaths worldwide by the end of the 21 st century. How genetic variation contributes to the observed differential predisposition in the human population to drug dependence is unknown. The zebrafish ( Danio rerio ) is an emerging vertebrate model system for understanding the genetics of behavior. We developed a nicotine behavioral assay in zebrafish and applied it in a forward genetic screen using gene-breaking transposon mutagenesis. We used this method to molecularly characterize bdav /cct8 and hbog /gabbr1.2 as mutations with altered nicotine response. Each have a single human ortholog, identifying two points for potential scientific, diagnostic, and drug development for nicotine biology and cessation therapeutics. We show this insertional method generates mutant alleles that are reversible through Cre-mediated recombination, representing a conditional mutation system for the zebrafish. The combination of this reporter-tagged insertional mutagen approach and zebrafish provides a powerful platform for a rich array of questions amenable to genetic-based scientific inquiry, including the basis of behavior, epigenetics, plasticity, stress, memory, and learning.
Large-Scale Analysis of DNA Methylation In Chronic Lymphocytic Leukemia
Rahmatpanah, Farahnaz, Carstens, Stephanie, Hooshmand, Sam , Welsh, Elise C, Sjahputera, Ozy, Taylor, Kristen H. , Bennett, Lynda , Shi, Huidong , Arthur, Gerald L., Wooldridge, James E. , Caldwell, Charles W., Davis, J. Wade , Shanafelt, Tait D. , Kay, Neil E.

Mayo Clinic

Epigenomics | October 6, 2009 | Volume: 1 | Issue: 1 | Pages: 39-61

10.2217/epi.09.10 | PMID 20495622 Get It

Novel Breast Tissue Feature Strongly Associated With Risk of Breast Cancer
McKian, Kevin P., Reynolds, Carol, Visscher, Daniel W., Nassar, Aziza , Vierkant, Robert A. , Ghosh, Karthik, Anderson, Stephanie S., Minot, Douglas M., Caudill, Jill L., Vachon, Celine M. , Frost, Marlene H., Hartmann, Lynn C. , Nassar, Aziza , Radisky, Derek C. , Degnim, Amy C. , Boughey, Judy C. , Vachon, Celine M. , Pankratz, V. Shane , Vierkant, Robert A

Mayo Clinic

Journal of Clinical Oncology | October 6, 2009 | Volume: 27 | Issue: 35 | Pages: 5893-5898

10.1200/jco.2008.21.5079 | PMID 19805686 Get It

Purpose Accurate, individualized risk prediction for breast cancer is lacking. Tissue-based features may help to stratify women into different risk levels. Breast lobules are the anatomic sites of origin of breast cancer. As women age, these lobular structures should regress, which results in reduced breast cancer risk. However, this does not occur in all women. Methods We have quantified the extent of lobule regression on a benign breast biopsy in 85 patients who developed breast cancer and 142 age-matched controls from the Mayo Benign Breast Disease Cohort, by determining number of acini per lobule and lobular area. We also calculated Gail model 5-year predicted risks for these women. Results There is a step-wise increase in breast cancer risk with increasing numbers of acini per lobule (P = .0004). Adjusting for Gail model score, parity, histology, and family history did not attenuate this association. Lobular area was similarly associated with risk. The Gail model estimates were associated with risk of breast cancer (P = .03). We examined the individual accuracy of these measures using the concordance (c) statistic. The Gail model c statistic was 0.60 (95% CI, 0.50 to 0.70); the acinar count c statistic was 0.65 (95% CI, 0.54 to 0.75). Combining acinar count and lobular area, the c statistic was 0.68 (95% CI, 0.58 to 0.78). Adding the Gail model to these measures did not improve the c statistic. Conclusion Novel, tissue-based features that reflect the status of a woman's normal breast lobules are associated with breast cancer risk. These features may offer a novel strategy for risk prediction.
Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer
Cicek, Mine , Achenbach, Sara J., French, Amy J. , Blair, Hilary, Fink, Stephanie, Foster, Nathan R. , Kabat, Brian, Halling, Kevin C. , Cunningham, Julie M. , Cerhan, James R. , Jenkins, Robert B. , Boardman, Lisa A., Petersen, Gloria M. , Sargent, Daniel J. , Thibodeau, Stephen N. , Slager, Susan L. , Boardman, Lisa A., Alberts, Steven R. , Limburg, Paul J. , Sargent, Daniel J , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 11, 2009 | Volume: 18 | Issue: 9 | Pages: 2492-2500

10.1158/1055-9965.epi-09-0362 | PMID 19690179 Get It

Abstract Multiple genome-wide association studies have identified several susceptibility variants for colon cancer at 8q24. However, the functional roles of these variants have yet to be elucidated. Here, we evaluated the potential role of these markers in tumor progression and examined association with commonly observed structural abnormalities in this region, c-MYC amplification and chromosome fragility at FRA8C and FRA8D. We first replicated the previously reported association by testing 1,178 cases and 1,009 clinic-based controls with eight markers localized to three specific regions at 8q24. We observed significant associations with colon cancer risk with markers rs13254738 (ordinal odds ratio, 0.82; 95% confidence interval, 0.072-0.94; Ptrend = 0.0037) and rs6983267 (ordinal odds ratio, 1.17; 95% confidence interval, 1.03-1.32, Ptrend = 0.013). Survival analysis was done using a separate set of 460 cases to evaluate the clinical significance of these markers. Overall, univariate analysis did not detect survival differences for any of the markers. We also tested a subset of the 460 cases (n = 380) for structural abnormalities at or near the c-MYC locus using fluorescence in situ hybridization analysis. Furthermore, we evaluated a small number of cases homozygous for the rs6983267 alleles to test for differences in fragile site induction. None of the 8q markers correlated with amplification at the c-MYC locus as detected by fluorescence in situ hybridization, and no clear pattern of breakage was observed at the FRA8C and FRA8D sites. In this study, we confirm the association for several single nucleotide polymorphisms at 8q24 in colon cancer but have not detected any structural role relating to c-MYC amplification or chromosomal fragility. Finally, these risk alleles do not seem to be associated with survival. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2492–500)
Quantifying Speech Rhythm Abnormalities in the Dysarthrias
White, Laurence , Lansford, Kaitlin L. , Lotto, Andrew J., Spitzer, Stephanie M., Caviness, John N., Liss, Julie , Mattys, Sven L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | August 28, 2009 | Volume: 52 | Issue: 5 | Pages: 1334-1352

10.1044/1092-4388(2009/08-0208) | PMID 19717656 Get It

Purpose In this study, the authors examined whether rhythm metrics capable of distinguishing languages with high and low temporal stress contrast also can distinguish among control and dysarthric speakers of American English with perceptually distinct rhythm patterns. Methods Acoustic measures of vocalic and consonantal segment durations were obtained for speech samples from 55 speakers across 5 groups (hypokinetic, hyperkinetic, flaccid-spastic, ataxic dysarthrias, and controls). Segment durations were used to calculate standard and new rhythm metrics. Discriminant function analyses (DFAs) were used to determine which sets of predictor variables (rhythm metrics) best discriminated between groups (control vs. dysarthrias; and among the 4 dysarthrias). A cross-validation method was used to test the robustness of each original DFA. Results The majority of classification functions were more than 80% successful in classifying speakers into their appropriate group. New metrics that combined successive vocalic and consonantal segments emerged as important predictor variables. DFAs pitting each dysarthria group against the combined others resulted in unique constellations of predictor variables that yielded high levels of classification accuracy. Conclusions This study confirms the ability of rhythm metrics to distinguish control speech from dysarthrias and to discriminate dysarthria subtypes. Rhythm metrics show promise for use as a rational and objective clinical tool.
HLA-DQB1*0602 Determines Disease Susceptibility in a New “Humanized” Multiple Sclerosis Model in HLA-DR15 (DRB1*1501;DQB1*0602) Transgenic Mice
Kaushansky, Nathali , Altmann, Daniel M. , Ascough, Stephanie , David, Chella S., Lassmann, Hans , Ben‐Nun, Avraham

Mayo Clinic

The Journal of Immunology | July 31, 2009 | Volume: 183 | Issue: 5 | Pages: 3531-3541

10.4049/jimmunol.0900784 | PMID 19648275 Get It

Abstract The susceptibility to multiple sclerosis (MS), a chronic neurological autoimmune disease that primarily targets CNS myelin, has long been associated with HLA class-II genes. Although several other HLA and non-HLA disease predisposing alleles have been identified, alleles of the HLA-DR15 haplotype (DRB1*1501, DRB5*0101, and DQB1*0602) remain the strongest susceptibility factor. Many studies have suggested that the HLA-DRB1*1501 allele determines MS-associated susceptibility. However, due to strong linkage disequilibrium within the HLA class II region, it has been difficult to unequivocally determine the relative roles of the DRB1*1501 and DQB1*0602 products. In this study we use HLA class-II transgenic mice to illuminate the relative contributions of the DRB1*1501 and DQB1*0602 alleles or their combination to susceptibility toward a new “humanized” MS-like disease induced by myelin-associated oligodendrocytic basic protein (MOBP). Although many immunological studies have focused overwhelmingly on the role of the HLA-DRB1*1501 product in MS, we show that HLA-DRB1*1501 transgenics are refractory to MOBP disease induction, whereas the HLA-DQB1*0602 transgenics are susceptible via T cells reactive against MOBP15–36 and MOBP55–77 encephalitogenic epitopes. Although both transgenics react against these epitopes, the MOBP15–36- and MOBP55–77-reactive T cells are of Th2-type in HLA-DRB1*1501 transgenics and are pathogenic Th1/Th17 cells in the HLA-DQB1*0602 transgenic mice. This new humanized model of MS further implicates autoimmunity against MOBP in MS pathogenesis, provides the first evidence of pathogenic HLA-DQ-associated anti-myelin autoimmunity, and is the first to offer a rationale for HLA-DQB1*0602 association with MS. These findings have important bearing on the candidacy of the DQB1*0602 allele as a genetic risk factor for MS.